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Abstract
With the quality by design (QbD) initiative, regulatory authorities demand a consis-
tent drug quality originating from a well-understood manufacturing process. This
study demonstrates the application of a previously published mechanistic chromatog-
raphy model to the in silico process characterization (PCS) of a monoclonal antibody
polishing step. The proposed modeling workflow covered the main tasks of tradi-
tional PCS studies following the QbD principles, including criticality assessment of
11 process parameters and establishment of their proven acceptable ranges of opera-
tion. Analyzing effects of multi-variate sampling of process parameters on the purifi-
cation outcome allowed identification of the edge-of-failure. Experimental validation
of in silico results demanded approximately 75% less experiments compared to a
purely wet-lab based PCS study. Stochastic simulation, considering the measured var-
iances of process parameters and loading material composition, was used to estimate
the capability of the process to meet the acceptance criteria for critical quality attri-
butes and key performance indicators. The proposed workflow enables the imple-
mentation of digital process twins as QbD tool for improved development of
biopharmaceutical manufacturing processes.
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1 | INTRODUCTION
The biopharmaceutical industry is under an unprecedented pres-
sure to implement technologies for rapid process development.
Main reasons are rising numbers of monoclonal antibodies (mAbs)
in development1,2 and strongly accelerated development time-
lines.3 While achieving a short time-to-market timeline, mAb man-
ufacturers have to ensure high product quality by following the
quality by design (QbD) concept. The QbD concept demands a
consistent product quality originating from an intrinsic quality built
into the design and the control of the manufacturing process. In
recent years, regulatory authorities and biopharmaceutical organi-
zations formulated clear concepts for the implementation of QbD
in pharmaceutical development.4–6 Yu et al.5 listed the key ele-
ments for a development strategy that complies with the QbD
concept:
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• A quality target product profile (QTPP) for the identification of crit-
ical quality attributes (CQAs) of the drug product
• Identification of critical material attributes (CMAs) and critical pro-
cess parameters (CPPs) potentially effecting CQAs
• Measuring the effect of CPPs and CMAs on CQAs
• Development of a control strategy
• Process capability and continual improvement.
Development workflows comprising the above listed QbD elements
make use of general process knowledge and statistical design of
experiments (DoE) for the characterization of a unit operation.7–9 For
many process steps, including preparative chromatography, it is not
feasible to include all controllable process parameters in a DoE study.
Even on small-scale systems,10 it is challenging to screen hundreds of
process conditions when considering the subsequent analytical bottle-
neck. Therefore, process parameters have to undergo a risk-based
criticality assessment considering their potential impact on CQAs
before designing an experimental process characterization study
(PCS).7,8 Risk-based decision trees for process parameter classification
are able to reduce the dimensionality of DoE studies, and thus reduce
the experimental burden for process development. However, parame-
ter criticality assessment can be influenced by subjective decision-
making caused by the lack of experimental data at this development
stage. As a result, incorrectly classified process parameters could lead
to avoidable experimental effort, or worse, to a poorly understood
control strategy. Further, PCS approaches based on DoE are limited
to regression models correlating CPPs to CQAs with a limited amount
of data points per CPP.
In the ICH Q8/Q9/Q10 (R2) documents,11 regulatory
authorities propose the use of mathematical models to support
bioprocess development and manufacturing. These models
include mechanistic models describing the physical phenomena
within a unit operation, which can be used to predict process
outcomes under varying conditions.11 Digitalization initiatives in
biopharma industry and academia identified mechanistic chro-
matography modeling as a promising tool for in silico develop-
ment of downstream processes (DSP).12–15 After overcoming
the initial hurdle of model calibration,16–20 mechanistic chroma-
tography models show a broad applicability to bioprocess
development, including process optimization,21 robustness
analysis,22–24 or scale-up.10,25 Recently, Andris et al.26 devel-
oped a mechanistic model for the separation of antibody-drug
conjugates. Their work allowed the characterization of a design
space, revealing the relevance of digital process twins in the
light of QbD. For ion exchange chromatography, Jakobsson
et al.24 used mechanistic modeling to design a robust pooling
strategy under consideration of model uncertainty. A mechanis-
tic modeling study performed by Close et al.22 identified robust
operating conditions for a hydrophobic interaction chromatog-
raphy process, where resin and loading material had a consid-
erable impact on process performance. Following the QbD
concept, Rischawy et al.27 used mechanistic modeling for the
identification of CPPs for a cation exchange chromatography
step applied to the polishing of a bispecific mAb. Shekhawat
et al.28 developed a model that improved understanding around
resin fouling in Protein A chromatography. The here mentioned
mechanistic modeling studies increased process understanding
or solved specific problems regarding process robustness. How-
ever, as described earlier, regulatory authorities defined clear
perspectives on the implementation of QbD in process devel-
opment and the related tasks. To the best of our knowledge, it
is still to be shown how mechanistic models could be applied
to a PCS study addressing the essential QbD elements.
Our previous publications introduced a quality system for mecha-
nistic chromatography modeling in biopharmaceutical process devel-
opment. The selection of representative experiments for model
calibration ensured adequate model certainty with minimal
resources.17 This mechanistic model was validated against data of
multiple scales, including clinical manufacturing-scale.29 As a sequel
of this publication series, the mechanistic model is applied to the PCS
of a cation-exchange chromatography (CEX) step. Simulations are per-
formed at manufacturing-scale avoiding limitation of experimental
scale-down model studies. The in silico strategy aims to fulfill the fun-
damental tasks of a PCS following the QbD concept. This includes
criticality assessment of process parameters and measuring their
effect on CQAs and key performance indicators (KPIs). Further, simu-
lations provide the database to identify proven acceptable ranges
(PARs) for process parameters as part of the control strategy. An
experimental design is derived from mechanistic model predictions to
reduce the experimental effort compared to wet-lab driven DoE
approaches. As a last element, Monte-Carlo simulation allows the cal-
culation of process capability under consideration of CPP, KPP, KMA,
and CMA variances measured during clinical manufacturing. The pres-
ented methodology generates in-depth process understanding follow-
ing the QbD concept, while debottlenecking experimental limitation
of DoE approaches. Mechanistic modeling for in silico PCS can
improve decision-making in DSP development, assuring product qual-
ity throughout the entire value chain.
2 | MODELING
Details about model discrimination, model parameters, the model cali-
bration strategy, and scale-dependent considerations can be found in
our previous publications.17,29 Protein-specific model parameters are
listed in Table 1. This section gives an overview on the mechanistic
model and complementations necessary for model-guided scale-up.
The one dimensional (1D) transport dispersive model was selected as
column model, due to multiple successful case studies for the simula-
tion of ion exchange chromatography systems.16,20,30–32 Equation (1)
describes the macroscopic transport of component i through the chro-
matography column. The change of the concentration ci at position x
in time t is a function of convective mass transport in the interstitial
volume, peak broadening caused by axial dispersion Dax, and mass
transfer from the interstitial volume into the pore phase of the particle
with the radius rP. Further, mass transfer between the interstitial
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volume and the particle pores is affected by the interstitial porosity
ϵcol and the effective mass transfer coefficient keff,i. The accumulation
of mass in the pore phase cp,i with the particle porosity ϵp and the sta-
tionary phase qi is described in Equation (2). The Danckwerts' bound-
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Linear flow rates ranged from 155 cm/h to 360 cm/h between inves-
tigated scales, demanding the introduction of flow dependencies for
the axial dispersion coefficient Dax and effective mass transfer param-
eter keff,i. The penetration correlation allowed the direct calculation
keff,i for monomer and high molecular weight (HMW) species at rele-
vant flow rates, respectively.33,34 Within the investigated range, flow
dependencies for Dax and keff,i could be approximated using linear
regression according to Equation (5) and (6).
Dax uð Þ¼Dax0þuDax1 ð5Þ
keff,i uð Þ¼ keff0,iþukeff1,i ð6Þ
Protein adsorption is simulated using the semi-mechanistic SMA
adsorption model.35 The multicomponent SMA model formulates
the equilibrium binding behavior of the protein in consideration of
the salt concentration in the pore phase cs, the ionic capacity of
the resin Λ, and the proteins characteristic charge νi. Equation (7)
shows the kinetic form of the SMA isotherm modified by Hahn
et al.,31 where keq,i = kads,i/kdes,i and kkin,i = 1/kdes,i describe adsorp-
tion and desorption rates of component i, respectively. In addition,
the steric shielding parameter σi denotes the number of functional
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The introduction of pH-dependent isotherm parameters is crucial for
industrial applications. Equations (9) and (10) show the empirical pH
dependencies of the characteristic charge νi and the equilibrium con-
stant keq,i developed by Hunt et al.
36 This model was found to be suf-
ficient for the process relevant pH range of pH 5.8 ± 0.3 used in this
study.17
keq,i pHð Þ¼ keq0,iekeq1,ipHþkeq2,ipH
2 ð9Þ
νi pHð Þ¼ ν0,iþpHν1,i ð10Þ
3 | MATERIAL AND METHODS
3.1 | CEX unit operation
The investigated protein is an IgG1 mAb expressed in stably trans-
fected Chinese hamster ovary cells (Boehringer Ingelheim GmbH &
Co. KG, Biberach, Germany). The mAb was captured via Protein A
affinity chromatography and further polished using anion
exchange chromatography in flow-through mode. The presented
mechanistic model describes the subsequent CEX unit operation
TABLE 1 Protein specific model parameters for the pH-dependent SMA model. Details regarding the model calibration procedure are
described in our previous publication.17 For a clear representation of model parameters at pH 5.8, the pH was normalized to zero. pH 5.5 = 0.3,
pH 5.8 = 0, pH 6.1 = 0.3
Parameter APG Main BPG HMW
keff0,i [mm/s] 1.4E-3 1.4E-3 1.4E-3 1.2E-3
keff1,i [] 4.7E-05 4.7E-05 4.7E-05 3.3E-05
νpH5.8,i [] 7.38 7.50 7.70 10.97
ν1,i [] 1.44 1.44 1.44 6.77
keq,pH 5.8,i [] 1.45 1.41 1.69 1.86
keq,1,i [] 4.26 4.26 4.26 5.39
keq,2,i [] 2.19 2.19 2.19 5.59
kkin,i [sM
ν] 8.08E-06 1.00E-04 5.00E-04 3.4E-05
σi [] 128.6 56.3 107.1 0
Abbreviations: APG, acidic; BPG, basic peak groups; HMW, high molecular weight species.
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using the strong CEX resin POROS 50 HS (Thermo Fisher Scien-
tific, Waltham, USA). The process was performed at constant
pH 5.8 in bind-elute mode and at a maximal load density of
45 g/Lresin. The column was equilibrated at a counter-ion concen-
tration of 87 mM Na+, with the same buffer applied to the wash
phase after column loading. Subsequently, elution was induced at
F IGURE 2 Decision tree for model-guided criticality assessment of process parameters and establishment of their proven acceptable ranges
(PARs). LAC, lower acceptance criterion; UAC, upper acceptance criterion
F IGURE 1 In silico process characterization of a unit operation for monoclonal antibody purification
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a counter-ion concentration of 247 mM Na+. For column regener-
ation and storage, 1 M and 0.1 M NaOH were applied respectively.
Selected experiments from wet-lab PCS studies were used to vali-
date the most critical relationships between process parameters
and CQAs/KPIs. Bench-scale experiments were performed on an
Äkta Avant 25 (Cytiva, Uppsala, Sweden) using an experimental
scale down model (SDM) column with a bed height of 300 mm and
an inner diameter of 10 mm.
Charge variant and HMW concentrations in the elution pool
were quantified using analytical CEX chromatography and analyti-
cal size exclusion chromatography, respectively. Acidic (APG), neu-
tral (Main) and basic peak groups (BPG), as well as HMW species
were considered as CQAs. Process step yield and elution volume
were defined as KPIs and quantified using protein concentration
determined via absorbance at 280 nm and gravimetric volume
measurement. Details of the model calibration and validation, as
well as analytical chromatography methods, are presented in one
of our previous publications.17
3.2 | In silico PCS workflow
This chapter describes the methodology of an in silico PCS following
the QbD concept. The PCS workflow consisted of three major build-
ing blocks: (1) Process parameter criticality assessment and establish-
ment of PARs; (2) Identification and validation of the edge-of-failure;
(3) Calculation of process capabilities. Protein- and system-specific
mechanistic model parameters were kept constant and were obtained
from our previous publications.17,29 Only process parameters were
varied during in silico sampling. All simulations were performed at
manufacturing-scale, under consideration of system and column
dimensions. Before starting in silico experimentation, the applied
mechanistic model was validated as digital representation of the real-
world process. Model validation must consider the intended purpose
of the model and its potential impact on the control strategy at
manufacturing-scale. Small-scale experiments validated that the model
captures the impact of process parameter variation on the purification
outcome.17 Model validation across scales showed that the model
captures relevant system effects and proofed equivalence between
the mechanistic model and manufacturing-scale.29 Based on this pre-
viously published validation strategy, it is reasonable to use the model
for in silico PCS.
Figure 1 depicts the three different parameter-sampling methods.
Initially, a one-factor-at-a-time sampling (OFAT) scheme enabled criti-
cality assessment of process parameters and definition of PARs. Dur-
ing OFAT sampling, one parameter was sampled in a wide range
around its intended set point, while the other process parameters
were kept constant. The loading density was sampled below its upper
limit of 45 g/Lresin. Following the decision tree in Figure 2, process
parameters were ranked as non-KPP, CPP, KPP, CMA or KMA based
on their effect on CQAs and KPIs.
• non-KPP: Process parameter does not affect a CQA or KPP
• CPP: Critical process parameter affects at least one CQA
• KPP: Key process parameter affects at least one KPI and not
affects CQAs
• CMA: Critical material attribute affects at least one CQA
• KMA: Key material attribute affects at least one KPI and not
affects CQAs
Subsequently, the same data obtained from OFAT sampling allowed
definition of PARs for all investigated process parameters. The estab-
lishment of PARs is a fundamental part of the control strategy and
represents the main goal of a PCS. According to the European Medi-
cines Agency (EMA) and ICH Q8 R2 guideline,11,37 the PAR is defined
as the operating range of a process parameter for which the unit oper-
ation will produce a drug substance meeting the relevant quality
criteria. When all process parameters are kept constant, but one
parameter varies within its PAR, all CQAs and KPIs measured in the
F IGURE 3 Monte-Carlo simulation for the calculation of process
capability. The stochastic simulation procedure considered loading
material compositions and input parameter distributions resulting in
the calculation of process capabilities for six critical quality attributes
(CQAs) and key performance indicators (KPIs). Exemplary input and
output distributions are shown
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elution pool must be located within their predefined acceptance
criteria (AC). Thus, OFAT sampling of input parameters is a suitable
method for the establishment of PARs. As presented in Figure 2, the
intersection of ACs and the curve obtained via in silico sampling
defined the lower and upper boundary of the PAR. If a process param-
eter did not cause CQAs or KPIs to violate the AC, the entire in silico
screened parameter range of this process parameter was defined
as PAR.
Process parameters ranked as CPPs and KPPs were analyzed in
subsequent multi-parametric sampling studies. The multi-parametric
sampling study represented the second building block of the in silico
PCS. Here, CPPs and KPPs were varied jointly to study the worst-case
operating scenarios. This procedure enabled the identification of the
edge-of-failure under consideration of the AC. Historical wet-lab
experiments at process conditions around the edge-of-failure were
used to validate the in silico findings.
In a last step, the process capability of the unit operation was cal-
culated based on stochastic simulation (Monte-Carlo simulation), as
described in Figure 3. Therefore, probability functions of process
parameters and loading material composition were calculated based
on 20 chromatographic cycles at clinical manufacturing-scale. Subse-
quently, 1000 simulations were performed using random samples of
the previously determined probability function as model input. The
resulting CQA and KPI distributions were then plotted and compared
to the AC. The standard deviations bσ obtained from in silico gener-
ated CQA and KPI distributions enabled calculation of the
corresponding process capabilities Cpl and Cpu for the lower and upper






For each CQA or KPI, the overall process capability Cpk was defined
as the minimum of Cpl and Cpu. When only an LAC or an UAC was
defined, the overall process capability could be simplified to Cpk = Cpl
or Cpk = Cpu.
4 | RESULTS AND DISCUSSION
In the following chapters, a previously published mechanistic chroma-
tography model was applied to the in silico PCS of a CEX unit opera-
tion.17,29 The multi-stage modeling workflow aimed to fulfill essential
tasks of PCS following the QbD concept. This includes CPP identifica-
tion and PAR definition. Multi-parametric effects on the purification
outcome were identified and validated with wet-lab experiments.
Monte-Carlo simulation allowed the determination of process capabil-
ity under consideration of real CPP, KPP, CMA, and loading material
composition variability.
4.1 | Parameter criticality assessment and control
strategy
Before starting characterization of a unit operation, process
parameters must be classified according to their impact on CQAs
and KPIs. The mechanistic chromatography model enabled effect
analysis of process parameters following an OFAT sampling
scheme. Table 2 lists the results of the parameter criticality assess-
ment following the decision tree in Figure 2. In silico investigation
of one process parameter consisted of 50 simulations, with equi-
distant steps in a wide range around the set-point condition. While
one parameter was varied, all other process parameters were kept
on the set point. Five process parameters were ranked as CPPs or
CMAs, showing effects on at least one CQA. Salt concentration in
the equilibration/wash buffer was ranked as KMA, since it only
affected the KPI step yield. All remaining process parameters were
TABLE 2 Criticality assessment of in silico screened process parameters of the CEX unit operation. Process parameters were classified
according to the decision tree depicted in Figure 2
Process parameter Unit Tested range Effect on CQA Effect on KPI Classification
pH elution buffer pH 5.5–6.1 Yes Yes CMA
Salt elution buffer mM Na+ 230–265 Yes Yes CMA
Flow rate elution cm/h 100–350 Yes Yes CPP
pH equilibration/wash buffer pH 5.5–6.1 Yes Yes CMA
Loading density g/Lresin 22.5–45 Yes Yes CPP
Salt equilibration/wash buffer mM Na+ 74–99 No Yes KMA
Flow rate loading cm/h 100–350 No No non-KPP
pH load pH 5.5–6.1 No No non-KPP
Salt load mM Na+ 62–85 No No non-KPP
Flow rate wash cm/h 100–350 No No non-KPP
Column length mm 270–330 No No non-KPP
Abbreviations: CEX, cation-exchange chromatography; CQA, critical quality attributes; KPI, key performance indicators.
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ranked as non-KPPs and did not affect CQAs or KPIs within the
screened parameter ranges.
Mobile phase pH and salt concentrations were amongst the pro-
cess parameters showing the strongest impact on CQAs and KPIs.
Thus, Figure 4 highlights the effects of mobile phase conditions during
equilibration/wash and elution on the purification result. The non-
linear correlation between elution pH and HMW concentration was
identified as the most considerable effect. The mechanistic model
predicted that an elution buffer with pH above pH 5.9 results
in HMW levels violating the upper AC. Typically, the initial
criticality-assessment of process parameters is based on failure mode
and effect analysis (FMEA). The FMEA allows a risk-ranking
depending on initial experiments and available data from process
development, historical knowledge from different mAbs at compara-
ble process steps, and process understanding of subject matter
experts. A validated mechanistic model could be used to support a
F IGURE 4 Criticality assessment of process parameters via in silico one-factor-at-a-time sampling (OFAT) sampling. The figure shows effects
of mobile phase conditions during elution and wash phase on critical quality attributes (CQAs) and key performance indicators (KPIs). Each sub-
figure contains the information of 50 simulations at varying process conditions (black line). Dashed red lines indicate the acceptance criteria for
CQAs and KPIs
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knowledge-based FMEA. The effects of potential CPPs and KPPs
identified via FMEA on CQAs and KPIs are then screened in a DoE
approach. The in silico OFAT screening allowed a rationalized identifi-
cation of critical input parameters without experimental limitations.
Process understanding leveraged from 550 simulations was used to
generate the parameter classifications given in Table 2. Such a number
of experiments containing similar amount of information cannot be
screened economically in wet-lab.
Following the methodology described in Section 3.2, upper and
lower limits for PARs (not presented in numbers) were directly derived
from the intersection of simulated data and predefined AC in
Figure 4. PARs can be established using wet-lab data obtained from
OFAT or DoE studies. Due to experimental limitations, data
evaluation is often limited to first- or second-degree regression
modeling. The data in Figure 4 reveals how the non-linear correlations
between CQAs and CPPs affect the establishment of PARs. Simple
regression modeling based on a small number of experiments would
result in different PARs. The in silico established PARs could be used
as part of the control strategy during commercial manufacturing. From
a regulatory perspective, the process understanding obtained via
OFAT sampling based on mechanistic modeling represents a Level
3 control strategy.5 The process control assures product quality meet-
ing the specifications when a single process parameter deviates within
its PAR. Further, the effect of deviating process parameters on CQAs
and KPIs is well-understood enabling the possibility to adapt controls
upstream in the process chain. Potentially, the mechanistic model
could be applied to a Level 1 control strategy, substituting traditional
testing of the intermediate product. In this case, continual generation
of in silico data would enable automated adjustment of process
parameters assuring a consistent product quality within the AC.5
Application of mechanistic models as soft-sensors in a Level 1 control
strategy could be useful for continuous manufacturing,38,39 when the
adoption of process analytical technology (PAT) is not feasible.
The applied mechanistic model considered large-scale column
dimensions and properties. Further, the model was validated against
manufacturing-scale data. Consequently, the mechanistic model
enabling in silico PAR definition was representative to the final
manufacturing-scale. Traditional DoE approaches rely on scale-down
experimentation. The ICH guidelines support the establishment of
PARs using small-scale experimentation. However, all simplifications
and assumptions made during SDM experimentation must be justified
during approval process. A pure in silico PCS is currently not rec-
ommended if not all CQAs are fully covered by the mechanistic model.
Therefore, the following section focusses on a minimal amount of
wet-lab experiments for validating the relevant correlations between
process parameters and CQAs and KPIs.
4.2 | Identification and validation of the edge-of-
failure
In the previous section, in silico OFAT screening enabled classification
of process parameters and establishment of PARs. This chapter aims
to validate the identified effects of process parameters on CQAs and
KPIs using experimental data obtained from previous wet-lab PCS
experiments. Here, the minimal number of experiments demanded for
validation of in silico results was compared to the experimental effort
of an entirely wet-lab based PCS. The multi-variate sampling investi-
gated effects on step yield and aggregate concentration.
Amongst the investigated parameters, mobile phase properties
showed the strongest impact on HMW removal and step yield. Mech-
anistic model predictions showed that an increased counter ion con-
centration and mobile phase pH during the wash phase caused an
early desorption of protein, negatively affecting step yield. Both
process parameters, wash salt concentration and wash pH, were
simultaneously varied in silico using a parametric sweep study
F IGURE 5 Effect of mobile phase conditions on step yield (a) and
HMW removal (b). Scatter plots show the results of wet-lab
experiments performed at process conditions close to the edge-of
-failure (green = within AC, red = outside AC). Red contours
represent the edge-of-failure, as the cutting line of model prediction
and AC. Each contour plot is calculated based on 400 simulations at
varying process conditions
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consisting of 400 simulations. As a result, Figure 5A shows step
yield as a function of mobile phase conditions during the wash
phase. The edge-of-failure was defined as the cutting curve of the
surface function calculated based on in silico results and the AC
for step yield. Set-point conditions for wash salt and pH conditions
are located in the center of x- and y-axis, respectively. Therefore,
the contour plot reveals that step yield cannot fall below the AC
when varying only one factor at a time. When increasing both, salt
and pH during wash above set-point conditions the step yield
drops from >98% to a minimum of 77% within the investigated
parameter space. Elution of protein during the wash phase resulted
in non-linear correlations between process parameters and step
yield, which would be difficult to cover using an experimentally
limited DoE approach coupled with empirical response surface
modeling. The selection of wet-lab experiments at conditions close
to the edge-of-failure (scatter plot in Figure 5) validated that a
F IGURE 6 Monte-Carlo simulation of the CEX unit operation at pH 5.8 during elution phase. Dashed red lines indicate acceptance criteria.
Each data point represents a simulation at 12000 L manufacturing-scale. Measurement data of 20 clinical manufacturing runs was used to
simulate the variance of load material composition, loading density, pH, and salt concentrations of the different chromatographic phases
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simultaneous increase of salt concentration and pH during the
wash phase would result in a violation of the AC for step yield.
Instead of conducting wet-lab experiments in the entire parameter
space, in silico identification of the edge-of-failure enabled a
reduction of the experimental design to process conditions rele-
vant for proofing process robustness.
The identical methodology was applied to mobile phase condi-
tions during the elution phase and their effect on HMW concen-
tration in the elution pool. Figure 5B depicts HMW concentration
as a function of elution salt concentration and elution
pH. Compared to elution salt concentration, the elution pH had a
strong impact on the HMW levels in the product. Again, wet-lab
experiments around the edge-of-failure could validate the correla-
tions obtained using in silico data. With targeted experiments close
to the in silico determined edge-of-failure, the total number of
wet-lab experiments was reduced from 35 to 9 compared to the
traditional DoE-based PCS. The contour plot in Figure 5B supports
the finding of the previous OFAT analysis, that elution pH 5.7
F IGURE 7 Monte-Carlo simulation of the CEX unit operation at pH 5.7 during elution phase. Dashed red lines indicate acceptance criteria.
Each data point represents one simulation at 12000 L manufacturing-scale. Measurement data of 20 clinical manufacturing runs was used to
simulate the variance of load material composition, loading density, pH, and salt concentrations of the different chromatographic phases
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could be a more robust set point, showing an increased distance to
the edge-of-failure compared to pH 5.8. The true capability of the
process to deplete HMW species in the desired quantity demands
further in silico analysis considering material and process parame-
ter variability.
4.3 | Process capability and continual
improvement
Following the QbD elements described by Yu et al., process capability
and continual improvement represents the final building block of the
in silico PCS.5 Process capability cpk describes the ability of the purifi-
cation process to achieve CQAs and KPIs located within the AC under
consideration of the intrinsic process variability. As depicted in
Figure 3, Monte-Carlo simulation enabled calculation of process capa-
bilities. Feed stream and process parameter variances were used as
model input. The input distributions were obtained from 20 CEX chro-
matography cycles at clinical manufacturing-scale. Variance in load
composition and mobile phase properties were approximated with
Gaussian functions. The input variance of the loading density was
described by a Gaussian function limited to a maximum of 45 g/Lresin.
The 1000 samples were taken from the distributions calculated based
on manufacturing-scale data. The intended mobile phase pH value of
the unit-operation was pH 5.8 for all chromatographic phases.
Although a pH range of pH 5.8 ± 0.1 is well controllable, simulations
in Figure 4 suggest that pH 5.7 is a more robust set point for HMW
removal. Therefore, both elution pH scenarios were evaluated using
the Monte-Carlo method. Figure 6 and Figure 7 show the resulting
distribution of CQAs and KPIs for pH 5.8 and 5.7, respectively.
The comparison between Figure 6 and Figure 7 reveals that a
reduction of the elution pH from pH 5.8 to pH 5.7 increases process
capability for HMW removal when considering the intrinsic variance
of the CEX unit operation. The capability of the process to achieve an
HMW concentration below the AC increased from 0.43 to 1.54.
Assuming normal distribution of model outputs, the probability for an
HMW concentration be located outside the AC reduced to 0.0004%
from 19.4%. The adaption of the elution set point pH had no negative
effect on process capabilities of other CQAs and KPIs. Consequently,
Monte-Carlo simulation could support the decision to shift the set
point pH from pH 5.8 to pH 5.7.
Despite the simplification of assuming normal distribution for the
majority of CPPs, KPIs, CMAs, and KMAs as model input, step yield
and elution volume showed an asymmetric distribution at pH 5.7.
These trends underline the importance of considering non-linear cor-
relations in preparative chromatography. Similar to the loading mate-
rial compositions, charge variant concentrations in the elution pool
were found to be normally distributed. Process capabilities for charge
variants ranged between 0.92 and 1.23. A cpk = 1 corresponds to a
distance of 3 sigma between the mean output value and the AC,
resulting in a 0.27% probability for a CQA or KPI to be located outside
the AC.
Probabilistic simulation using mechanistic modeling is a simple
and effective way to estimate process capabilities before a sufficient
amount of real data from commercial manufacturing campaigns is
available. Here, adaption of the set point pH based on Monte-Carlo
simulation improved process robustness with regards to aggregate
removal and reduced the risk of an out of specification (OOS) event.
During the product lifecycle, input distributions for CMAs, KMAs,
CPPs. and KPPs can be continuously updated and fed-back into the
mechanistic model. This procedure would allow an early identification
of root-causes for process variability enabling an adjustment of the
control strategy if needed.
5 | CONCLUSION
In the present study, a mechanistic chromatography model was
applied to the PCS of mAb polishing step. The in silico method-
ology fulfilled the essential elements of the QbD concept. OFAT
sampling allowed classification of process parameters and estab-
lishment of PARs. Wet-lab studies derived from in silico screen-
ing can lead to a significantly reduced experimental effort
compared to purely DoE driven PCS studies. Calculation of pro-
cess capability considering a posteriori variabilities of feed
stream materials and process parameters at manufacturing-scale
enabled the identification of a robust set point condition. In this
study, in silico PCS results were complemented with experimen-
tal data, which reduced the overall impact of mechanistic model-
ing on the control strategy. When relying exclusively on in silico
predictions, consideration of the effects of model parameter
uncertainty on model predictions will further increase the trust
in the final control strategy.
Considering the complexity of polishing chromatography steps
compared to other unit operations in mAb purification processes
and the related experimental efforts that must be invested for
their characterization, the here presented in silico techniques have
the potential to debottleneck process development timelines.
While accelerating development and disrupting experimental con-
straints, mechanistic modeling generated a deep process under-
standing ensuring consistent product quality in the light of QbD.
This work represents a possible concept for the application of digi-
tal process twins to QbD related tasks in biopharmaceutical pro-
cess development, with the focus on preparative chromatography.
The proposed methods could further enable the in silico PCS of
other unit operations when validated mechanistic models are
available.
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